Senior Correspondent, London
Ben's Feed
Jan 30, 2015
Jan 29, 2015
Jan 29, 2015

Stoppard’s new play lifts the lid on brain science

LONDON, Jan 29 (Reuters) – Tom Stoppard, the grand old man
of British theatre, is back with his first new stage play in
nine years, tackling typically big ideas: consciousness, science
and God.

“The Hard Problem” is a 100-minute gallop, with no interval,
through neurobiology, religion and improbable “black swan”
events in financial markets that is both contemporary and
timeless. Along the way there are tales of altruistic vampire
bats and some good jokes.

Jan 29, 2015
Jan 29, 2015
Jan 29, 2015

AstraZeneca bets on gene editing for broad range of new drugs

LONDON (Reuters) – AstraZeneca said on Thursday it had struck four research collaborations in the hot area of genome editing as it bets on a new technology to deliver better and more precise drugs for a range of diseases.

The academic and commercial tie-ups will allow British-based AstraZeneca to use so-called CRISPR technology across its entire drug discovery platform in areas such as oncology, cardiovascular, respiratory and immune system medicine.

Jan 27, 2015
Jan 27, 2015
Jan 26, 2015
Jan 24, 2015
    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben